Quintiles-Invested Samsung Biologics Proceeds On Schedule
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's largest conglomerate Samsung Group announced April 22 the CEO and the company name of a joint venture with Quintiles Transnational Corp. making inroads into the biosimilar and biopharmaceutical business